---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-025326"
form_type: "8-K"
ticker: "LQDA"
cik: "0001819576"
company_name: "Liquidia Corp"
filed_at: "2025-03-19T23:59:59+00:00"
generated_at: "2026-05-24T12:04:16.618557+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Liquidia targets final YUTREPIA approval May 23, 2025; FY 2024 net loss $130.4M

## Summary
- FY 2024 revenue $14.0M (down from $17.5M) driven by Treprostinil Injection promotion; net loss $130.4M ($1.66/share) vs $78.5M loss prior year.
- FDA tentative approval of YUTREPIA (PAH/PH-ILD) granted Aug 2024; final approval expected after NCI exclusivity expires May 23, 2025.
- HCRx financing amended for up to $100M: $25M received at closing, $50M contingent on first YUTREPIA sale, $25M upon $100M net sales milestone.
- Cash and equivalents $176.5M at Dec 31, 2024, up from $83.7M a year earlier.
- ASCENT study (YUTREPIA in PH-ILD) nearing enrollment completion; L606 (liposomal treprostinil) U.S. open-label study ongoing.

## SEC filing metadata
- accession: 0001104659-25-025326
- form_type: 8-K
- ticker: LQDA
- cik: 0001819576
- company_name: Liquidia Corp
- filed_at: 2025-03-19T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819576/000110465925025326/0001104659-25-025326-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819576/000110465925025326/tm259683d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-025326
- JSON: https://secwatch.observer/filing/0001104659-25-025326.json
- Plain text: https://secwatch.observer/filing/0001104659-25-025326.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.